Founded in 1890 as the first manufacturer of electric fans in North America, Emerson Electric has become a leading industrial automation player through the acquisition of established brands... Show more
Emerson Electric has completed a multi-year transformation into a pure-play industrial automation and software company. Following the roughly $7.2 billion acquisition of the remaining AspenTech shares in 2025 and the full integration of National Instruments, Emerson now spans process control, discrete automation, test and measurement, and an expanding industrial software stack. This repositioning gives it high switching costs in critical plants, a durable installed base, and a growing recurring-revenue layer.
Its competitive set includes Siemens, ABB, Honeywell, Rockwell Automation, Schneider Electric, and Yokogawa, each with distinct niches. Emerson's medium-term edge lies in combining domain-specific process knowledge with software-defined control and AI-driven optimization, areas where its next-generation DeltaV and Ovation control platforms and AspenTech analytics create a more integrated offering. However, competition is intensifying around AI-native industrial software, and Emerson must demonstrate that its new tools convert into measurable customer savings and sustained software growth.
The next meaningful inflection point is Emerson's fiscal fourth-quarter earnings report, scheduled for early November 2026. Investors will focus on order trends, backlog conversion, software annual contract value (ACV, a measure of recurring subscription commitments), and any update to the company's margin trajectory.
Beyond earnings, product momentum is building. Recent launches include the AspenTech AVA AI platform, the expanded NI Nigel AI test-software suite, and the Ovation Virtual Advisor, alongside partnerships with SiMa.ai and L&T Technology Services. Management has signaled that quoting activity for new AI offerings is already substantial, suggesting commercial adoption could be a meaningful sentiment driver.
Analyst actions have skewed constructive. J.P. Morgan, Mizuho, RBC Capital, Bernstein, Evercore ISI, and UBS have maintained or raised Buy ratings and price targets in recent months, while Wells Fargo initiated coverage with a Buy. The consensus average price target sits near $175, with a high around $205 and a low near $104. Still, Morgan Stanley's reiterated "Sell" and a $145 target underscores that valuation and execution risks remain contested.
Emerson's fortunes are closely tied to global industrial capital expenditure. Rising power demand—driven by data centers, electrification, and grid modernization—along with LNG buildout and semiconductor investment are structural tailwinds. These long-cycle projects provide multi-year revenue visibility but also make the company sensitive to interest rates, which influence customers' financing costs and project timing.
Commodity and energy price trends shape process-industry spending, while inflation affects input costs and pricing. Geopolitical developments, particularly in the Middle East, can delay energy projects; Emerson has already assumed a near-term impact while also anticipating repair and restart work. Meanwhile, softness in China and Europe remains a drag on its test and measurement and discrete automation businesses, making geographic mix a key swing factor.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool that helps traders assess whether a stock, exchange-traded fund (ETF), or other asset may move bullish, bearish, or sideways over the coming week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad range of tradable instruments, with searchable prediction categories, historical context, and alert-oriented functionality. For those monitoring Emerson or similar names, the engine offers an additional analytical lens to complement fundamental research.
Looking into 2026 and beyond, Emerson's trajectory hinges on three structural themes. First, its pivot toward higher-value software and AI promises a richer earnings mix if adoption meets expectations. Second, the secular electrification and energy-transition cycle should sustain demand across power, LNG, and grid infrastructure. Third, management's shift in capital allocation—toward share repurchases of roughly $1 billion and dividends of about $1.2 billion in fiscal 2026—signals confidence in cash generation and a maturing of the acquisition-heavy phase.
Consensus estimates project revenue rising from about $18.9 billion in fiscal 2026 toward nearly $20 billion in fiscal 2027, with earnings per share (EPS) expected to grow from roughly $6.57 to around $7.26. These figures are external analyst expectations, not forecasts. Key risks include slower-than-expected software monetization, elevated debt, persistent China and Europe weakness, and competitive pressure in AI-driven industrial automation. How Emerson navigates these variables will determine whether its margin-expansion story continues to resonate.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, EMR has been closely correlated with AME. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if EMR jumps, then AME could also see price increases.
| Ticker / NAME | Correlation To EMR | 1D Price Change % | ||
|---|---|---|---|---|
| EMR | 100% | +1.79% | ||
| AME - EMR | 74% Closely correlated | +0.33% | ||
| IR - EMR | 70% Closely correlated | +0.65% | ||
| ROK - EMR | 70% Closely correlated | +1.18% | ||
| LECO - EMR | 69% Closely correlated | -1.15% | ||
| GTES - EMR | 66% Closely correlated | +2.04% | ||
More | ||||
| Ticker / NAME | Correlation To EMR | 1D Price Change % |
|---|---|---|
| EMR | 100% | +1.79% |
| EMR (6 stocks) | 82% Closely correlated | -2.75% |
| Producer Manufacturing (346 stocks) | 14% Poorly correlated | +11.92% |
a developer of process controls systems, valves and analytical instruments
Industry IndustrialMachinery
Be on the lookout for a price bounce soon.
EMR moved above its 50-day moving average on November 18, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where EMR advanced for three days, in 219 of 345 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 164 of 274 cases where EMR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.
The 10-day RSI Indicator for EMR moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 similar instances where the indicator moved out of overbought territory. In 21 of the 42 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EMR as a result. In 57 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 63%.
The Moving Average Convergence Divergence Histogram (MACD) for EMR turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 22 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 50%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
EMR broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. EMR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.444) is normal, around the industry mean (3.843). P/E Ratio (35.370) is within average values for comparable stocks, (36.971). Projected Growth (PEG Ratio) (1.837) is also within normal values, averaging (1.879). Dividend Yield (0.015) settles around the average of (0.032) among similar stocks. P/S Ratio (4.409) is also within normal values, averaging (189.487).